nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—PDE8A—mammary gland—lung cancer	0.0222	0.112	CbGeAlD
Flavoxate—PDE4A—mammary gland—lung cancer	0.0178	0.0901	CbGeAlD
Flavoxate—PDE8B—bronchus—lung cancer	0.0135	0.0685	CbGeAlD
Flavoxate—PDE8A—bronchus—lung cancer	0.0122	0.0616	CbGeAlD
Flavoxate—PDE7B—lung—lung cancer	0.011	0.0555	CbGeAlD
Flavoxate—PDE8A—trachea—lung cancer	0.0109	0.0553	CbGeAlD
Flavoxate—PDE8A—cardiac atrium—lung cancer	0.0103	0.052	CbGeAlD
Flavoxate—Hyperpyrexia—Paclitaxel—lung cancer	0.00962	0.0444	CcSEcCtD
Flavoxate—PDE8B—lung—lung cancer	0.00873	0.0442	CbGeAlD
Flavoxate—PDE8A—lung—lung cancer	0.00785	0.0398	CbGeAlD
Flavoxate—PDE7B—lymph node—lung cancer	0.0075	0.038	CbGeAlD
Flavoxate—PDE4D—lung—lung cancer	0.00712	0.036	CbGeAlD
Flavoxate—PDE4B—respiratory system—lung cancer	0.00707	0.0358	CbGeAlD
Flavoxate—PDE4A—lung—lung cancer	0.0063	0.0319	CbGeAlD
Flavoxate—PDE8B—lymph node—lung cancer	0.00597	0.0302	CbGeAlD
Flavoxate—PDE4B—bronchus—lung cancer	0.00582	0.0295	CbGeAlD
Flavoxate—PDE8A—lymph node—lung cancer	0.00537	0.0272	CbGeAlD
Flavoxate—PDE4B—trachea—lung cancer	0.00523	0.0265	CbGeAlD
Flavoxate—PDE4B—cardiac atrium—lung cancer	0.00491	0.0249	CbGeAlD
Flavoxate—PDE4D—lymph node—lung cancer	0.00487	0.0246	CbGeAlD
Flavoxate—CHRM1—trachea—lung cancer	0.00472	0.0239	CbGeAlD
Flavoxate—Vision blurred—Crizotinib—lung cancer	0.00468	0.0216	CcSEcCtD
Flavoxate—Leukopenia—Crizotinib—lung cancer	0.00444	0.0205	CcSEcCtD
Flavoxate—PDE4A—lymph node—lung cancer	0.00431	0.0218	CbGeAlD
Flavoxate—PDE4B—bone marrow—lung cancer	0.00414	0.021	CbGeAlD
Flavoxate—Leukopenia—Pemetrexed—lung cancer	0.00406	0.0187	CcSEcCtD
Flavoxate—Skin disorder—Crizotinib—lung cancer	0.00393	0.0182	CcSEcCtD
Flavoxate—PDE4B—lung—lung cancer	0.00375	0.019	CbGeAlD
Flavoxate—Dry mouth—Gefitinib—lung cancer	0.00375	0.0173	CcSEcCtD
Flavoxate—Skin disorder—Pemetrexed—lung cancer	0.0036	0.0166	CcSEcCtD
Flavoxate—Skin disorder—Gefitinib—lung cancer	0.00357	0.0165	CcSEcCtD
Flavoxate—CHRM1—lung—lung cancer	0.00339	0.0172	CbGeAlD
Flavoxate—Leukopenia—Teniposide—lung cancer	0.00329	0.0152	CcSEcCtD
Flavoxate—Confusional state—Teniposide—lung cancer	0.00302	0.014	CcSEcCtD
Flavoxate—Urticaria—Pemetrexed—lung cancer	0.00294	0.0136	CcSEcCtD
Flavoxate—Tachycardia—Teniposide—lung cancer	0.00293	0.0135	CcSEcCtD
Flavoxate—Urticaria—Gefitinib—lung cancer	0.00292	0.0135	CcSEcCtD
Flavoxate—Vomiting—Crizotinib—lung cancer	0.00258	0.0119	CcSEcCtD
Flavoxate—PDE4B—lymph node—lung cancer	0.00257	0.013	CbGeAlD
Flavoxate—Vertigo—Vinblastine—lung cancer	0.00252	0.0116	CcSEcCtD
Flavoxate—Leukopenia—Vinblastine—lung cancer	0.00251	0.0116	CcSEcCtD
Flavoxate—Feeling abnormal—Teniposide—lung cancer	0.00247	0.0114	CcSEcCtD
Flavoxate—Leukopenia—Topotecan—lung cancer	0.00244	0.0113	CcSEcCtD
Flavoxate—Nausea—Crizotinib—lung cancer	0.00241	0.0111	CcSEcCtD
Flavoxate—Urticaria—Teniposide—lung cancer	0.00238	0.011	CcSEcCtD
Flavoxate—Vomiting—Pemetrexed—lung cancer	0.00235	0.0109	CcSEcCtD
Flavoxate—Vomiting—Gefitinib—lung cancer	0.00234	0.0108	CcSEcCtD
Flavoxate—Nausea—Pemetrexed—lung cancer	0.0022	0.0102	CcSEcCtD
Flavoxate—Nausea—Gefitinib—lung cancer	0.00218	0.0101	CcSEcCtD
Flavoxate—Skin disorder—Topotecan—lung cancer	0.00216	0.00997	CcSEcCtD
Flavoxate—Skin disorder—Erlotinib—lung cancer	0.00214	0.00986	CcSEcCtD
Flavoxate—Vertigo—Vinorelbine—lung cancer	0.00209	0.00966	CcSEcCtD
Flavoxate—Leukopenia—Vinorelbine—lung cancer	0.00208	0.00963	CcSEcCtD
Flavoxate—Palpitations—Vinorelbine—lung cancer	0.00206	0.0095	CcSEcCtD
Flavoxate—Vomiting—Teniposide—lung cancer	0.00191	0.0088	CcSEcCtD
Flavoxate—Feeling abnormal—Vinblastine—lung cancer	0.00188	0.0087	CcSEcCtD
Flavoxate—Headache—Teniposide—lung cancer	0.00188	0.00867	CcSEcCtD
Flavoxate—Tachycardia—Vinorelbine—lung cancer	0.00186	0.00857	CcSEcCtD
Flavoxate—Skin disorder—Vinorelbine—lung cancer	0.00185	0.00853	CcSEcCtD
Flavoxate—Feeling abnormal—Topotecan—lung cancer	0.00183	0.00846	CcSEcCtD
Flavoxate—Nausea—Teniposide—lung cancer	0.00178	0.00822	CcSEcCtD
Flavoxate—Urticaria—Topotecan—lung cancer	0.00177	0.00815	CcSEcCtD
Flavoxate—Vertigo—Irinotecan—lung cancer	0.00173	0.00797	CcSEcCtD
Flavoxate—Leukopenia—Irinotecan—lung cancer	0.00172	0.00794	CcSEcCtD
Flavoxate—Leukopenia—Gemcitabine—lung cancer	0.00167	0.00773	CcSEcCtD
Flavoxate—Vision blurred—Cisplatin—lung cancer	0.00164	0.00759	CcSEcCtD
Flavoxate—Confusional state—Irinotecan—lung cancer	0.00158	0.0073	CcSEcCtD
Flavoxate—Feeling abnormal—Vinorelbine—lung cancer	0.00157	0.00723	CcSEcCtD
Flavoxate—Leukopenia—Cisplatin—lung cancer	0.00156	0.00721	CcSEcCtD
Flavoxate—Tension—Paclitaxel—lung cancer	0.00154	0.0071	CcSEcCtD
Flavoxate—Nervousness—Paclitaxel—lung cancer	0.00152	0.00703	CcSEcCtD
Flavoxate—Urticaria—Vinorelbine—lung cancer	0.00151	0.00697	CcSEcCtD
Flavoxate—Skin disorder—Gemcitabine—lung cancer	0.00148	0.00685	CcSEcCtD
Flavoxate—Vision blurred—Paclitaxel—lung cancer	0.00148	0.00682	CcSEcCtD
Flavoxate—Vomiting—Vinblastine—lung cancer	0.00145	0.00672	CcSEcCtD
Flavoxate—Vertigo—Etoposide—lung cancer	0.00144	0.00663	CcSEcCtD
Flavoxate—Headache—Vinblastine—lung cancer	0.00143	0.00662	CcSEcCtD
Flavoxate—Leukopenia—Etoposide—lung cancer	0.00143	0.0066	CcSEcCtD
Flavoxate—Vomiting—Topotecan—lung cancer	0.00141	0.00652	CcSEcCtD
Flavoxate—Vertigo—Paclitaxel—lung cancer	0.00141	0.0065	CcSEcCtD
Flavoxate—Leukopenia—Paclitaxel—lung cancer	0.0014	0.00648	CcSEcCtD
Flavoxate—Vomiting—Erlotinib—lung cancer	0.0014	0.00645	CcSEcCtD
Flavoxate—Somnolence—Irinotecan—lung cancer	0.00139	0.00644	CcSEcCtD
Flavoxate—Headache—Topotecan—lung cancer	0.00139	0.00643	CcSEcCtD
Flavoxate—Tachycardia—Cisplatin—lung cancer	0.00139	0.00641	CcSEcCtD
Flavoxate—Palpitations—Paclitaxel—lung cancer	0.00138	0.00639	CcSEcCtD
Flavoxate—Skin disorder—Cisplatin—lung cancer	0.00138	0.00638	CcSEcCtD
Flavoxate—Headache—Erlotinib—lung cancer	0.00138	0.00636	CcSEcCtD
Flavoxate—Eosinophilia—Methotrexate—lung cancer	0.00136	0.00628	CcSEcCtD
Flavoxate—Nausea—Vinblastine—lung cancer	0.00136	0.00627	CcSEcCtD
Flavoxate—Somnolence—Gemcitabine—lung cancer	0.00136	0.00627	CcSEcCtD
Flavoxate—Nausea—Topotecan—lung cancer	0.00132	0.00609	CcSEcCtD
Flavoxate—Confusional state—Etoposide—lung cancer	0.00131	0.00607	CcSEcCtD
Flavoxate—Nausea—Erlotinib—lung cancer	0.00131	0.00603	CcSEcCtD
Flavoxate—Dry mouth—Paclitaxel—lung cancer	0.0013	0.00602	CcSEcCtD
Flavoxate—Feeling abnormal—Irinotecan—lung cancer	0.00129	0.00597	CcSEcCtD
Flavoxate—Confusional state—Paclitaxel—lung cancer	0.00129	0.00595	CcSEcCtD
Flavoxate—Tachycardia—Etoposide—lung cancer	0.00127	0.00588	CcSEcCtD
Flavoxate—Skin disorder—Etoposide—lung cancer	0.00127	0.00585	CcSEcCtD
Flavoxate—Feeling abnormal—Gemcitabine—lung cancer	0.00126	0.00581	CcSEcCtD
Flavoxate—Tachycardia—Paclitaxel—lung cancer	0.00125	0.00576	CcSEcCtD
Flavoxate—Skin disorder—Paclitaxel—lung cancer	0.00124	0.00573	CcSEcCtD
Flavoxate—Drowsiness—Methotrexate—lung cancer	0.00122	0.00565	CcSEcCtD
Flavoxate—Vomiting—Vinorelbine—lung cancer	0.00121	0.00558	CcSEcCtD
Flavoxate—Headache—Vinorelbine—lung cancer	0.00119	0.0055	CcSEcCtD
Flavoxate—Leukopenia—Docetaxel—lung cancer	0.00119	0.00549	CcSEcCtD
Flavoxate—Eosinophilia—Doxorubicin—lung cancer	0.00118	0.00544	CcSEcCtD
Flavoxate—Palpitations—Docetaxel—lung cancer	0.00117	0.00542	CcSEcCtD
Flavoxate—Feeling abnormal—Cisplatin—lung cancer	0.00117	0.00542	CcSEcCtD
Flavoxate—Somnolence—Etoposide—lung cancer	0.00116	0.00535	CcSEcCtD
Flavoxate—Somnolence—Paclitaxel—lung cancer	0.00114	0.00525	CcSEcCtD
Flavoxate—Nausea—Vinorelbine—lung cancer	0.00113	0.00521	CcSEcCtD
Flavoxate—Dry mouth—Docetaxel—lung cancer	0.00111	0.00511	CcSEcCtD
Flavoxate—Confusional state—Docetaxel—lung cancer	0.00109	0.00505	CcSEcCtD
Flavoxate—Feeling abnormal—Etoposide—lung cancer	0.00107	0.00496	CcSEcCtD
Flavoxate—Drowsiness—Doxorubicin—lung cancer	0.00106	0.0049	CcSEcCtD
Flavoxate—Tachycardia—Docetaxel—lung cancer	0.00106	0.00488	CcSEcCtD
Flavoxate—Feeling abnormal—Paclitaxel—lung cancer	0.00105	0.00486	CcSEcCtD
Flavoxate—Skin disorder—Docetaxel—lung cancer	0.00105	0.00486	CcSEcCtD
Flavoxate—Urticaria—Etoposide—lung cancer	0.00104	0.00478	CcSEcCtD
Flavoxate—Antrafenine—PTGS2—lung cancer	0.00102	1	CrCbGaD
Flavoxate—Urticaria—Paclitaxel—lung cancer	0.00102	0.00469	CcSEcCtD
Flavoxate—Vomiting—Irinotecan—lung cancer	0.000997	0.0046	CcSEcCtD
Flavoxate—Headache—Irinotecan—lung cancer	0.000982	0.00453	CcSEcCtD
Flavoxate—Vomiting—Gemcitabine—lung cancer	0.000971	0.00448	CcSEcCtD
Flavoxate—Somnolence—Docetaxel—lung cancer	0.000963	0.00445	CcSEcCtD
Flavoxate—Headache—Gemcitabine—lung cancer	0.000957	0.00442	CcSEcCtD
Flavoxate—Nausea—Irinotecan—lung cancer	0.000931	0.0043	CcSEcCtD
Flavoxate—Nausea—Gemcitabine—lung cancer	0.000907	0.00419	CcSEcCtD
Flavoxate—Vomiting—Cisplatin—lung cancer	0.000905	0.00418	CcSEcCtD
Flavoxate—Vision blurred—Methotrexate—lung cancer	0.000902	0.00416	CcSEcCtD
Flavoxate—Feeling abnormal—Docetaxel—lung cancer	0.000893	0.00412	CcSEcCtD
Flavoxate—Vertigo—Methotrexate—lung cancer	0.00086	0.00397	CcSEcCtD
Flavoxate—Leukopenia—Methotrexate—lung cancer	0.000857	0.00396	CcSEcCtD
Flavoxate—Nausea—Cisplatin—lung cancer	0.000845	0.0039	CcSEcCtD
Flavoxate—Vomiting—Etoposide—lung cancer	0.000829	0.00383	CcSEcCtD
Flavoxate—Headache—Etoposide—lung cancer	0.000817	0.00377	CcSEcCtD
Flavoxate—Tension—Doxorubicin—lung cancer	0.000813	0.00375	CcSEcCtD
Flavoxate—Vomiting—Paclitaxel—lung cancer	0.000813	0.00375	CcSEcCtD
Flavoxate—Nervousness—Doxorubicin—lung cancer	0.000805	0.00372	CcSEcCtD
Flavoxate—Headache—Paclitaxel—lung cancer	0.000801	0.0037	CcSEcCtD
Flavoxate—Confusional state—Methotrexate—lung cancer	0.000788	0.00364	CcSEcCtD
Flavoxate—Vision blurred—Doxorubicin—lung cancer	0.000781	0.00361	CcSEcCtD
Flavoxate—Nausea—Etoposide—lung cancer	0.000775	0.00358	CcSEcCtD
Flavoxate—Nausea—Paclitaxel—lung cancer	0.000759	0.00351	CcSEcCtD
Flavoxate—Skin disorder—Methotrexate—lung cancer	0.000759	0.0035	CcSEcCtD
Flavoxate—Vertigo—Doxorubicin—lung cancer	0.000745	0.00344	CcSEcCtD
Flavoxate—Leukopenia—Doxorubicin—lung cancer	0.000742	0.00343	CcSEcCtD
Flavoxate—Palpitations—Doxorubicin—lung cancer	0.000732	0.00338	CcSEcCtD
Flavoxate—Somnolence—Methotrexate—lung cancer	0.000694	0.00321	CcSEcCtD
Flavoxate—Dry mouth—Doxorubicin—lung cancer	0.00069	0.00319	CcSEcCtD
Flavoxate—Vomiting—Docetaxel—lung cancer	0.000689	0.00318	CcSEcCtD
Flavoxate—Confusional state—Doxorubicin—lung cancer	0.000682	0.00315	CcSEcCtD
Flavoxate—Headache—Docetaxel—lung cancer	0.000679	0.00313	CcSEcCtD
Flavoxate—Tachycardia—Doxorubicin—lung cancer	0.00066	0.00305	CcSEcCtD
Flavoxate—Skin disorder—Doxorubicin—lung cancer	0.000657	0.00303	CcSEcCtD
Flavoxate—Nausea—Docetaxel—lung cancer	0.000644	0.00297	CcSEcCtD
Flavoxate—Feeling abnormal—Methotrexate—lung cancer	0.000644	0.00297	CcSEcCtD
Flavoxate—Urticaria—Methotrexate—lung cancer	0.000621	0.00287	CcSEcCtD
Flavoxate—Somnolence—Doxorubicin—lung cancer	0.000601	0.00278	CcSEcCtD
Flavoxate—Feeling abnormal—Doxorubicin—lung cancer	0.000557	0.00257	CcSEcCtD
Flavoxate—Urticaria—Doxorubicin—lung cancer	0.000537	0.00248	CcSEcCtD
Flavoxate—Vomiting—Methotrexate—lung cancer	0.000497	0.00229	CcSEcCtD
Flavoxate—Headache—Methotrexate—lung cancer	0.000489	0.00226	CcSEcCtD
Flavoxate—Nausea—Methotrexate—lung cancer	0.000464	0.00214	CcSEcCtD
Flavoxate—Vomiting—Doxorubicin—lung cancer	0.00043	0.00199	CcSEcCtD
Flavoxate—Headache—Doxorubicin—lung cancer	0.000424	0.00196	CcSEcCtD
Flavoxate—Nausea—Doxorubicin—lung cancer	0.000402	0.00186	CcSEcCtD
Flavoxate—PDE4C—Signaling Pathways—SRC—lung cancer	6.15e-05	0.000105	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CG—lung cancer	6.15e-05	0.000105	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CASP3—lung cancer	6.14e-05	0.000105	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IL2—lung cancer	6.14e-05	0.000105	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FLT1—lung cancer	6.13e-05	0.000105	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CXCL8—lung cancer	6.11e-05	0.000104	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—IL6—lung cancer	6.1e-05	0.000104	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APP—lung cancer	6.07e-05	0.000104	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NOTCH3—lung cancer	6.07e-05	0.000104	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—PIK3CA—lung cancer	6.07e-05	0.000104	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—HRAS—lung cancer	6.07e-05	0.000104	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CG—lung cancer	6.07e-05	0.000104	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MDM2—lung cancer	6.05e-05	0.000103	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—RAF1—lung cancer	6.03e-05	0.000103	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FGF9—lung cancer	6.02e-05	0.000103	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NOTCH3—lung cancer	6e-05	0.000103	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APP—lung cancer	6e-05	0.000103	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—VEGFA—lung cancer	5.99e-05	0.000102	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CCND1—lung cancer	5.98e-05	0.000102	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—JUN—lung cancer	5.97e-05	0.000102	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—ERBB2—lung cancer	5.96e-05	0.000102	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FGF9—lung cancer	5.95e-05	0.000102	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—STAT3—lung cancer	5.93e-05	0.000101	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—NRAS—lung cancer	5.92e-05	0.000101	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—AKT1—lung cancer	5.9e-05	0.000101	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3CB—lung cancer	5.88e-05	0.000101	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MTOR—lung cancer	5.88e-05	0.000101	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—AKT1—lung cancer	5.86e-05	0.0001	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—POMC—lung cancer	5.85e-05	0.0001	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CASP3—lung cancer	5.85e-05	0.0001	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IL2—lung cancer	5.84e-05	9.98e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—IL6—lung cancer	5.81e-05	9.93e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MMP9—lung cancer	5.81e-05	9.93e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CDKN1A—lung cancer	5.79e-05	9.89e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—POMC—lung cancer	5.78e-05	9.88e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PTEN—lung cancer	5.77e-05	9.87e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—JUNB—lung cancer	5.75e-05	9.83e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCND1—lung cancer	5.69e-05	9.73e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—JUN—lung cancer	5.68e-05	9.71e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—JUNB—lung cancer	5.68e-05	9.71e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MAPK3—lung cancer	5.67e-05	9.69e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CXCL8—lung cancer	5.65e-05	9.67e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—AKT1—lung cancer	5.63e-05	9.63e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—HRAS—lung cancer	5.62e-05	9.6e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CG—lung cancer	5.58e-05	9.54e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MMP9—lung cancer	5.53e-05	9.45e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CG—lung cancer	5.51e-05	9.42e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MYC—lung cancer	5.51e-05	9.42e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CDKN1A—lung cancer	5.51e-05	9.42e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—EP300—lung cancer	5.51e-05	9.41e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PTEN—lung cancer	5.49e-05	9.39e-05	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—AKT1—lung cancer	5.46e-05	9.34e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CASP3—lung cancer	5.41e-05	9.25e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CD—lung cancer	5.4e-05	9.24e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL2—lung cancer	5.4e-05	9.24e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—EGFR—lung cancer	5.39e-05	9.22e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—IL6—lung cancer	5.38e-05	9.19e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—AKT1—lung cancer	5.36e-05	9.16e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—SRC—lung cancer	5.35e-05	9.15e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CD—lung cancer	5.34e-05	9.12e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—POMC—lung cancer	5.31e-05	9.08e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCND1—lung cancer	5.27e-05	9.01e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—JUN—lung cancer	5.26e-05	8.99e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—POMC—lung cancer	5.25e-05	8.97e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—EP300—lung cancer	5.24e-05	8.96e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—STK11—lung cancer	5.22e-05	8.93e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—VEGFA—lung cancer	5.21e-05	8.91e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL6R—lung cancer	5.18e-05	8.86e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—STAT3—lung cancer	5.16e-05	8.83e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—STK11—lung cancer	5.16e-05	8.82e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—NRAS—lung cancer	5.15e-05	8.8e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL6R—lung cancer	5.12e-05	8.75e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MMP9—lung cancer	5.11e-05	8.74e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CDKN1A—lung cancer	5.1e-05	8.71e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—SRC—lung cancer	5.1e-05	8.71e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—KRAS—lung cancer	5.09e-05	8.71e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PTEN—lung cancer	5.08e-05	8.69e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FOXO3—lung cancer	5.04e-05	8.62e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FOXO3—lung cancer	4.98e-05	8.51e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—VEGFA—lung cancer	4.96e-05	8.48e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—AKT1—lung cancer	4.96e-05	8.48e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—MAP2K1—lung cancer	4.94e-05	8.45e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MAPK3—lung cancer	4.93e-05	8.43e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—STAT3—lung cancer	4.91e-05	8.4e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CD—lung cancer	4.91e-05	8.39e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—NRAS—lung cancer	4.9e-05	8.38e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—MAP2K1—lung cancer	4.88e-05	8.34e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—EP300—lung cancer	4.85e-05	8.29e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CD—lung cancer	4.84e-05	8.28e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MYC—lung cancer	4.8e-05	8.2e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AVP—lung cancer	4.72e-05	8.08e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—SRC—lung cancer	4.72e-05	8.06e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CB—lung cancer	4.71e-05	8.05e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MAPK3—lung cancer	4.7e-05	8.03e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—EGFR—lung cancer	4.69e-05	8.02e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—PIK3CA—lung cancer	4.68e-05	8e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AVP—lung cancer	4.66e-05	7.97e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CB—lung cancer	4.65e-05	7.95e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—VEGFA—lung cancer	4.59e-05	7.85e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MYC—lung cancer	4.57e-05	7.81e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IGF1R—lung cancer	4.55e-05	7.77e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—STAT3—lung cancer	4.55e-05	7.77e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—NRAS—lung cancer	4.54e-05	7.75e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CXCL8—lung cancer	4.53e-05	7.74e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—TP53—lung cancer	4.53e-05	7.74e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IGF1R—lung cancer	4.49e-05	7.67e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CXCL8—lung cancer	4.47e-05	7.64e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HES1—lung cancer	4.47e-05	7.64e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—EGFR—lung cancer	4.47e-05	7.64e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—KRAS—lung cancer	4.43e-05	7.58e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HES1—lung cancer	4.41e-05	7.54e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—RAF1—lung cancer	4.38e-05	7.49e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MAPK3—lung cancer	4.34e-05	7.43e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—HRAS—lung cancer	4.33e-05	7.4e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—IL2—lung cancer	4.33e-05	7.4e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—RAF1—lung cancer	4.33e-05	7.39e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CB—lung cancer	4.28e-05	7.31e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—IL2—lung cancer	4.27e-05	7.3e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MYC—lung cancer	4.23e-05	7.22e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CB—lung cancer	4.22e-05	7.22e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—KRAS—lung cancer	4.22e-05	7.21e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—IL6—lung cancer	4.14e-05	7.08e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—EGFR—lung cancer	4.13e-05	7.07e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CXCL8—lung cancer	4.11e-05	7.03e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ERBB3—lung cancer	4.08e-05	6.98e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PIK3CA—lung cancer	4.07e-05	6.96e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CXCL8—lung cancer	4.06e-05	6.94e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ERBB3—lung cancer	4.03e-05	6.89e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—TP53—lung cancer	3.94e-05	6.74e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL2—lung cancer	3.93e-05	6.72e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TERT—lung cancer	3.91e-05	6.69e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—KRAS—lung cancer	3.9e-05	6.67e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL2—lung cancer	3.88e-05	6.63e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PIK3CA—lung cancer	3.88e-05	6.63e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TERT—lung cancer	3.86e-05	6.61e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—AKT1—lung cancer	3.82e-05	6.53e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FGFR1—lung cancer	3.8e-05	6.5e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—HRAS—lung cancer	3.77e-05	6.44e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FGFR1—lung cancer	3.75e-05	6.41e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—TP53—lung cancer	3.75e-05	6.41e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HIF1A—lung cancer	3.74e-05	6.4e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HIF1A—lung cancer	3.7e-05	6.32e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APOA1—lung cancer	3.61e-05	6.18e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IL6—lung cancer	3.61e-05	6.17e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3CA—lung cancer	3.59e-05	6.13e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—HRAS—lung cancer	3.59e-05	6.13e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—KDR—lung cancer	3.58e-05	6.12e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APOA1—lung cancer	3.57e-05	6.1e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—KDR—lung cancer	3.53e-05	6.04e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—TP53—lung cancer	3.47e-05	5.93e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IL6—lung cancer	3.43e-05	5.87e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—AKT1—lung cancer	3.33e-05	5.69e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—HRAS—lung cancer	3.32e-05	5.67e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—KIT—lung cancer	3.3e-05	5.64e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APC—lung cancer	3.3e-05	5.64e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CG—lung cancer	3.3e-05	5.64e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—NRAS—lung cancer	3.3e-05	5.64e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EGF—lung cancer	3.26e-05	5.57e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—KIT—lung cancer	3.26e-05	5.57e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APC—lung cancer	3.26e-05	5.57e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CG—lung cancer	3.26e-05	5.57e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—NRAS—lung cancer	3.26e-05	5.57e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EGF—lung cancer	3.22e-05	5.5e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL6—lung cancer	3.18e-05	5.43e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—AKT1—lung cancer	3.17e-05	5.41e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—MAPK3—lung cancer	3.16e-05	5.4e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—POMC—lung cancer	3.14e-05	5.37e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—MAPK3—lung cancer	3.12e-05	5.33e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—BRAF—lung cancer	3.1e-05	5.3e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—POMC—lung cancer	3.1e-05	5.3e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL6R—lung cancer	3.06e-05	5.24e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—BRAF—lung cancer	3.06e-05	5.23e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CREBBP—lung cancer	3.06e-05	5.23e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL6R—lung cancer	3.02e-05	5.17e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CREBBP—lung cancer	3.02e-05	5.16e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—EGFR—lung cancer	3e-05	5.14e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—EGFR—lung cancer	2.97e-05	5.07e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—AKT1—lung cancer	2.93e-05	5.01e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MAP2K1—lung cancer	2.92e-05	4.99e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CD—lung cancer	2.9e-05	4.96e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MAP2K1—lung cancer	2.88e-05	4.93e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	2.87e-05	4.91e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CD—lung cancer	2.86e-05	4.89e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—KRAS—lung cancer	2.84e-05	4.85e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CA—lung cancer	2.83e-05	4.85e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—KRAS—lung cancer	2.8e-05	4.79e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	2.61e-05	4.46e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MDM2—lung cancer	2.6e-05	4.44e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—RAF1—lung cancer	2.59e-05	4.42e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CA—lung cancer	2.57e-05	4.4e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MDM2—lung cancer	2.56e-05	4.38e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ERBB2—lung cancer	2.56e-05	4.38e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—RAF1—lung cancer	2.56e-05	4.37e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ERBB2—lung cancer	2.53e-05	4.32e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CB—lung cancer	2.53e-05	4.32e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MTOR—lung cancer	2.53e-05	4.32e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MTOR—lung cancer	2.49e-05	4.26e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CB—lung cancer	2.49e-05	4.26e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CXCL8—lung cancer	2.43e-05	4.15e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—HRAS—lung cancer	2.41e-05	4.12e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CXCL8—lung cancer	2.4e-05	4.1e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—HRAS—lung cancer	2.38e-05	4.07e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AKT1—lung cancer	2.35e-05	4.01e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CASP3—lung cancer	2.32e-05	3.97e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL2—lung cancer	2.32e-05	3.97e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AKT1—lung cancer	2.32e-05	3.96e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL6—lung cancer	2.31e-05	3.95e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CASP3—lung cancer	2.29e-05	3.92e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL2—lung cancer	2.29e-05	3.92e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL6—lung cancer	2.28e-05	3.9e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCND1—lung cancer	2.26e-05	3.87e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—JUN—lung cancer	2.26e-05	3.86e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCND1—lung cancer	2.23e-05	3.82e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—JUN—lung cancer	2.23e-05	3.81e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MMP9—lung cancer	2.2e-05	3.76e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CDKN1A—lung cancer	2.19e-05	3.74e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PTEN—lung cancer	2.18e-05	3.73e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MMP9—lung cancer	2.17e-05	3.71e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CDKN1A—lung cancer	2.16e-05	3.69e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PTEN—lung cancer	2.16e-05	3.69e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT1—lung cancer	2.13e-05	3.64e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT1—lung cancer	2.1e-05	3.6e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EP300—lung cancer	2.08e-05	3.56e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EP300—lung cancer	2.06e-05	3.51e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SRC—lung cancer	2.03e-05	3.46e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SRC—lung cancer	2e-05	3.42e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—VEGFA—lung cancer	1.97e-05	3.37e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—STAT3—lung cancer	1.95e-05	3.34e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NRAS—lung cancer	1.95e-05	3.33e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—VEGFA—lung cancer	1.95e-05	3.33e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—STAT3—lung cancer	1.93e-05	3.3e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NRAS—lung cancer	1.92e-05	3.29e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MAPK3—lung cancer	1.87e-05	3.19e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MAPK3—lung cancer	1.84e-05	3.15e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MYC—lung cancer	1.81e-05	3.1e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MYC—lung cancer	1.79e-05	3.06e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EGFR—lung cancer	1.77e-05	3.03e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EGFR—lung cancer	1.75e-05	3e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—KRAS—lung cancer	1.68e-05	2.87e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—KRAS—lung cancer	1.66e-05	2.83e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CA—lung cancer	1.54e-05	2.63e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CA—lung cancer	1.52e-05	2.6e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TP53—lung cancer	1.49e-05	2.55e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TP53—lung cancer	1.47e-05	2.52e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HRAS—lung cancer	1.43e-05	2.44e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HRAS—lung cancer	1.41e-05	2.41e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL6—lung cancer	1.36e-05	2.33e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL6—lung cancer	1.35e-05	2.3e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT1—lung cancer	1.26e-05	2.15e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT1—lung cancer	1.24e-05	2.12e-05	CbGpPWpGaD
